News

Dr Brawer will assist GTx chief medical officer Ronald Morton, Jr, and vice president of medical affairs Shontelle Dodson in educating the medical community about disease states of

Acorda received a refuse to file (RTF) letter for the Fampridine-SR new drug application (NDA) on March 30, 2009, which cited the need to correct ‘format issues’ and

Prior to joining Biocodex Inc, Mr Rohman was part of the senior management team at FlowMedica in Fremont, California, where he was responsible for directing the company’s collaboration

The company has reported net income available to common shareholders of $767 million for the first quarter of 2009 compared to $276 million for the same quarter of

For the first quarter of 2009, total sales were $5.38 billion, a decrease of 8%, compared to $5.82 billion in the same quarter of 2008. Richard Clark, chairman,

Net income attributable to Gilead was $589.11 million or $0.63 diluted earnings per share, for the first quarter of 2009, compared to $488.30 million, or $0.51 diluted earnings

According to the company, Mecan, a European medical device and supplies distributor will be providing logistics and warehouse services for the MedX European distribution center. Following receipt of

The new service provides biopharmaceutical clients with a comprehensive way to measure the genetics of drug metabolism in clinical trial patients – giving drug developers the opportunity to

Amgen reported diluted earnings per share of $0.98 for the first quarter of 2009, a decrease of 3%, compared to $1.01 per share for the first quarter of